These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 17312111)

  • 1. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.
    Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA
    Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
    Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
    PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice.
    Verma SK; Kumar S; Gupta N; Vedi S; Bhattacharya SM; Lakshmana Rao PV
    Vaccine; 2009 Nov; 27(49):6905-9. PubMed ID: 19761840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.
    Martina BE; Koraka P; van den Doel P; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2008 Jan; 26(2):153-7. PubMed ID: 18069096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.
    Ramanathan MP; Kutzler MA; Kuo YC; Yan J; Liu H; Shah V; Bawa A; Selling B; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Jul; 27(32):4370-80. PubMed ID: 19497647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.
    Zlatkovic J; Stiasny K; Heinz FX
    J Virol; 2011 Mar; 85(5):1994-2003. PubMed ID: 21147919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus.
    Li SH; Li XF; Zhao H; Jiang T; Deng YQ; Yu XD; Zhu QY; Qin ED; Qin CF
    Immunol Lett; 2011 Aug; 138(2):156-60. PubMed ID: 21515306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
    Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
    J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.